Literature DB >> 30117081

Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens.

XiangQing Song1, MingHui Long2.   

Abstract

Background Continual evolution of resistance among bacteria against methods of surgical prophylaxis may make currently used beta-lactam regimens inadequate. Objective To re-evaluate beta-lactam regimens in surgical prophylaxis. Setting A pharmacodynamic Monte Carlo simulation (MCS) model based on a number of patients in China. Methods Pharmacodynamic profiling using Monte Carlo simulation up to 4 hours postinfusion was conducted for standard-dose, short-term (0.5 h) and prolonged (2 to 4 h) infusions of ampicillin, cefazolin, cefotaxime, cefoxitin, cefuroxime, ertapenem, and piperacillin/tazobactam in adult patients with normal renal function. Microbiological data were incorporated. Cumulative fraction of response (CFR) was determined for each regimen against populations of S. aureus, coagulase-negative staphylococci and E. coli. The optimal CFR was defined as ≥ 90% response. Main Outcome Measure Cumulative fractions of response of pharmacodynamic target attainment. Results During the first 2 hours postinfusion, piperacillin/tazobactam 3.375 g exhibited consistently optimal cumulative fractions against S. aureus, CoNS and E. coli. Ampicillin 2 g (2 h) also displayed optimal CFRs for S. aureus and E. coli but not for coagulase-negative staphylococci. Cefoxitin 2 g didnot achieve any optimal CFRs, even via 2-h prolonged infusion (maximum 72.8% CFR for S. aureus and 64.5% CFR for E. coli). Cefazolin 2 g (4 h) and cefuroxime 1.5 g (4 h) provided desired CFRs across 4 h postinfusion for S. aureus but provided poor CFRs for coagulase-negative staphylococci and E. coli. Only ertapenem 1 g for E. coli and S. aureus and cefotaxime 1 g for E. coli consistently yielded ≥ 90% CFRs for 4 hour postinfusion. Conclusions Certain dosing regimens may warrant adjustment for improved prevention efficiency and enhanced empirical antibiotic regimens for surgical prophylaxis.

Entities:  

Keywords:  Antibiotic prophylaxis; Beta-lactam; Cumulative fraction of response; Model-based evaluation; Monte Carlo simulation; Pharmacodynamics; Pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 30117081     DOI: 10.1007/s11096-018-0720-y

Source DB:  PubMed          Journal:  Int J Clin Pharm


  37 in total

1.  Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.

Authors:  Pornpan Koomanachai; Catharine C Bulik; Joseph L Kuti; David P Nicolau
Journal:  Clin Ther       Date:  2010-04       Impact factor: 3.393

2.  Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.

Authors:  R M Brown; R Wise; J M Andrews; J Hancox
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

3.  Antibiotic prophylaxis with cefuroxime in arthroplasty of the knee.

Authors:  D P Johnson
Journal:  J Bone Joint Surg Br       Date:  1987-11

4.  Pharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgery.

Authors:  A Wildfeuer; V Müller; M Springsklee; H G Sonntag
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

5.  Application of Pharmacodynamic Profiling for the Selection of Optimal β-lactam Regimens in a Large University Hospital.

Authors:  Pornpan Koomanachai; Thitiya Yungyuen; Pensiri Disthaporn; Pattarachai Kiratisin; David P Nicolau
Journal:  Int J Infect Dis       Date:  2016-03-25       Impact factor: 3.623

6.  Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.

Authors:  Hui Wang; Bo Zhang; Yuxing Ni; Joseph L Kuti; Baiyi Chen; Minjun Chen; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2007-07-23       Impact factor: 5.283

7.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

Authors:  Peggy S McKinnon; Joseph A Paladino; Jerome J Schentag
Journal:  Int J Antimicrob Agents       Date:  2008-03-04       Impact factor: 5.283

8.  Continuous versus intermittent infusion of prophylactic cefoxitin after colorectal surgery: a pilot study.

Authors:  Terri J Suffoletta; Heath R Jennings; Jennifer J Oh; Dana Stephens; Kevin L Poe
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

9.  Obstetric Surgical Site Infections: 2 Grams Compared With 3 Grams of Cefazolin in Morbidly Obese Women.

Authors:  Homa K Ahmadzia; Emily M Patel; Dipa Joshi; Caiyun Liao; Frank Witter; R Phillips Heine; Jenell S Coleman
Journal:  Obstet Gynecol       Date:  2015-10       Impact factor: 7.661

10.  Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.

Authors:  Francesca Mattioli; Carmen Fucile; Valerio Del Bono; Valeria Marini; Andrea Parisini; Alexandre Molin; Maria Laura Zuccoli; Giulia Milano; Romano Danesi; Anna Marchese; Marialuisa Polillo; Claudio Viscoli; Paolo Pelosi; Antonietta Martelli; Antonello Di Paolo
Journal:  Eur J Clin Pharmacol       Date:  2016-04-06       Impact factor: 2.953

View more
  3 in total

1.  Predicted Vancomycin Dosage Requirement in Patients With Hematological Malignancies and Dosage Dynamic Adjustment.

Authors:  Xiangqing Song; Yi Wu
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

2.  Competence Mining of Vancomycin (VAN) in the Management of Infections Due to Bacterial Strains With High VAN Minimum Inhibitory Concentrations (MICs): A Novel Dosing Strategy Based on Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Xiangqing Song; Meizi Zeng; Yi Wu; Yong Pan
Journal:  Front Microbiol       Date:  2021-04-22       Impact factor: 5.640

3.  Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections in Critically Ill Patients: Focus on Novel Infusion Mode.

Authors:  Xiangqing Song; Mi Han
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.